Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Appointed director
CC transcript
CATALYST BIOSCIENCES, INC. (CBIO) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Unaudited interim condensed consolidated financial statements of Beijing Continent as of and for the six months ended June 30, 2023"
05/05/2023 8-K Quarterly results
03/21/2023 8-K Quarterly results
03/02/2023 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial State...
Docs: "ASSET PURCHASE AGREEMENT",
"CATALYST AND GNI URGE INVESTORS AND STOCKHOLDERS TO READ THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT CATALYST, GNI, THE GNI TRANSACTIONS AND RELATED MATTERS."
01/19/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/27/2022 8-K Investor presentation
Docs: "by and among CATALYST BIOSCIENCES, INC., as the Buyer, and GNI GROUP LTD., and GNI HONG KONG LIMITED, as the Sellers Dated as of December 26, 2022",
"BUSINESS COMBINATION AGREEMENT",
"Certificate of Designation of Series X Convertible Preferred Stock",
"Amended and Restated Bylaws of Catalyst Biosciences, Inc",
"“Agreement”) is made and entered into as of [date] between Catalyst Biosciences, Inc., a Delaware corporation , and [name of director], a director, officer or member of the executive committee of the Company (“Indemnitee”",
"Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction",
"Presentation for investor conference call held by Catalyst Biosciences, Inc. on December 27, 2022"
11/04/2022 8-K Quarterly results
08/25/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
08/19/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
08/01/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Agreement, effective as of July 31, 2022, between Catalyst Biosciences, Inc. and certain Investors specified therein",
"Catalyst Biosciences Announces Support from Largest Single Stockholder"
07/11/2022 8-K Quarterly results
06/24/2022 8-K Quarterly results
06/08/2022 8-K Quarterly results
05/23/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
02/18/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
01/25/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Treatment of CFI Deficiency"
01/12/2022 8-K Investor presentation
Docs: "Presentation slide deck"
11/12/2021 8-K Quarterly results
Docs: "Catalyst Biosciences Announces Change in Corporate Strategy Reports Third Quarter 2021 Operating & Financial Results"
10/15/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Equity Distribution Agreement, between Catalyst Biosciences, Inc. and Piper Sandler & Co",
"Opinion of Orrick, Herrington & Sutcliffe LLP"
10/13/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Consulting Agreement between Catalyst Biosciences, Inc. and Clinton Musil",
"Catalyst Biosciences Announces Chief Financial Officer Transition"
09/29/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"FDA Grants Catalyst Biosciences Orphan Drug Designation for MarzAA for the Treatment of Factor VII Deficiency"
09/28/2021 8-K Quarterly results
09/08/2021 8-K Quarterly results
09/07/2021 8-K Quarterly results
08/16/2021 8-K Quarterly results
08/05/2021 8-K Investor presentation, Quarterly results
Docs: "Catalyst Biosciences Reports Second Quarter 2021 Operating & Financial Results and Provides a Corporate Update",
"Presentation slide deck"
07/22/2021 8-K Quarterly results
07/19/2021 8-K Investor presentation
Docs: "Complement Presentation slide deck",
"Corporate Presentation slide deck"
07/16/2021 8-K Investor presentation
Docs: "ARDS Complement Presentation slide deck",
"ARDS Complement Presentation slide deck"
07/15/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Original Employment Agreement between Grant Blouse and Catalyst Biosciences, Inc.",
"Amendment to Original Employment Agreement between Grant Blouse and Catalyst Biosciences, Inc., effective as of July 1, 2021"
06/29/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Factor VII Deficiency Second Fast Track Designation for MarzAA"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy